Boiron SA

ENXTPA:BOI Stock Report

Market Cap: €538.2m

Boiron Valuation

Is BOI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BOI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BOI (€31) is trading below our estimate of fair value (€115.5)

Significantly Below Fair Value: BOI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BOI?

Key metric: As BOI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BOI. This is calculated by dividing BOI's market cap by their current earnings.
What is BOI's PE Ratio?
PE Ratio22.7x
Earnings€23.69m
Market Cap€538.23m

Price to Earnings Ratio vs Peers

How does BOI's PE Ratio compare to its peers?

The above table shows the PE ratio for BOI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.7x
VETO Vetoquinol
20.6x8.9%€971.4m
VIRP Virbac
19.5x10.8%€2.7b
IPN Ipsen
13.3x7.0%€8.8b
GNFT Genfit
9.5x41.2%€210.5m
BOI Boiron
22.7x26.2%€538.2m

Price-To-Earnings vs Peers: BOI is expensive based on its Price-To-Earnings Ratio (22.7x) compared to the peer average (15.7x).

Price to Earnings Ratio vs Industry

How does BOI's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
BOI 22.7xIndustry Avg. 21.1xNo. of Companies7PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BOI is expensive based on its Price-To-Earnings Ratio (22.7x) compared to the European Pharmaceuticals industry average (21.2x).

Price to Earnings Ratio vs Fair Ratio

What is BOI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BOI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.7x
Fair PE Ratio20.5x

Price-To-Earnings vs Fair Ratio: BOI is expensive based on its Price-To-Earnings Ratio (22.7x) compared to the estimated Fair Price-To-Earnings Ratio (20.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BOI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€31.00
€33.30
+7.4%
18.9%€39.60€27.00n/a2
Nov ’25€32.60
€33.30
+2.1%
18.9%€39.60€27.00n/a2
Oct ’25€32.75
€33.30
+1.7%
18.9%€39.60€27.00n/a2
Apr ’25€33.62
€40.87
+21.6%
3.1%€42.14€39.60n/a2
Mar ’25€35.60
€40.46
+13.7%
2.9%€42.14€39.60n/a3
Feb ’25€39.50
€40.46
+2.4%
2.9%€42.14€39.60n/a3
Jan ’25€40.22
€40.46
+0.6%
2.9%€42.14€39.60n/a3
Dec ’24€40.50
€40.46
-0.1%
2.9%€42.14€39.60n/a3
Nov ’24€40.35
€43.93
+8.9%
10.0%€50.00€39.64€32.603
Oct ’24€53.70
€47.38
-11.8%
11.8%€52.50€39.64€32.753
Sep ’24€51.70
€46.21
-10.6%
10.1%€50.00€39.64€32.953
Aug ’24€50.70
€46.21
-8.8%
10.1%€50.00€39.64€32.003
Jul ’24€39.20
€48.67
+24.1%
5.9%€52.00€45.00€30.003
Jun ’24€37.15
€48.67
+31.0%
5.9%€52.00€45.00€35.953
May ’24€39.90
€51.67
+29.5%
4.0%€54.00€49.00€34.303
Apr ’24€39.70
€51.67
+30.1%
4.0%€54.00€49.00€33.623
Mar ’24€41.60
€53.00
+27.4%
5.6%€57.00€50.00€35.603
Feb ’24€41.95
€53.00
+26.3%
5.6%€57.00€50.00€39.503
Jan ’24€50.70
€53.67
+5.9%
5.3%€57.00€50.00€40.223
Dec ’23€45.60
€53.67
+17.7%
5.3%€57.00€50.00€40.503
Nov ’23€45.75
€53.67
+17.3%
5.3%€57.00€50.00€40.353

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sanofi

€114.5b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€91.31

7D

-4.6%

1Y

6.3%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

7D

-1.2%

1Y

-57.1%

Eurofins Scientific

€8.6b

Provides various analytical testing and laboratory services worldwide.

ERF

€45.44

7D

-0.3%

1Y

-13.7%